Download PDF
Thromb Haemost 2015; 114(01): 1-3
DOI: 10.1160/TH15-04-0297
Invited Editorial Focus
Schattauer GmbH

Is risk-benefit of warfarin for atrial fibrillation with heart failure determined by heart failure severity?

Andrew P. Sindone
1   Heart Failure Unit and Department of Cardiac Rehabilitation, Concord Hospital, Sydney, Australia
2   Sydney Medical School, Concord Clinical School, Dept of Cardiology, Concord Hospital, University of Sydney, Australia
,
Ben S. Freedman
2   Sydney Medical School, Concord Clinical School, Dept of Cardiology, Concord Hospital, University of Sydney, Australia
3   Anzac Research Institute, University of Sydney, Concord Hospital, Sydney, Australia
› Author Affiliations
Further Information

Publication History

Received: 10 April 2015

Accepted: 10 April 2015

Publication Date:
22 November 2017 (online)

Also available at
    Permissions and Reprints

Editorial Focus on: Kim et al. Thromb Haemost 2015; 114: 70–77.

 

  • References

  • 1 Rose AJ. et al. Patient characteristics associated with oral anticoagulation control: results of the Veterans AffaiRs Study to Improve Anticoagulation (VARIA). J Thromb Haemost 2010; 08: 2182-2191.
    CrossrefPubMedGoogle Scholar
  • 2 Connolly SJ. et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008; 118: 2029-2037.
    CrossrefPubMedGoogle Scholar
  • 3 Hylek EM. et al. Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin. Ann Intern Med 2001; 135: 393-400.
    CrossrefPubMedGoogle Scholar
  • 4 Rose A. et al. Warfarin for atrial fibrillation in community-based practice. J Thromb Haemost 2008; 06: 1647-1654.
    CrossrefPubMedGoogle Scholar
  • 5 Wan Y. et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes 2008; 01: 84-91.
    CrossrefPubMedGoogle Scholar
  • 6 De Caterina R. et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013; 110: 1087-1107.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Apostolakis S. et al. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT[two.inferior]R[two.inferior] score. Chest 2013; 144: 1555-1563.
    CrossrefPubMedGoogle Scholar
  • 8 Lip GY. et al. Relationship of the SAMe-TT[two.inferior]R[two.inferior] score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation. Chest 2014; 146: 719-726.
    CrossrefPubMedGoogle Scholar
  • 9 Agarwal M. et al. The impact of heart failure and left ventricular dysfunction in predicting stroke, thromboembolism, and mortality in atrial fibrillation patients: a systematic review. Clin Ther 2014; 36: 1135-1144.
    CrossrefPubMedGoogle Scholar
  • 10 Khatibzadeh S. et al. Worldwide risks for heart failure. Int J Cardiol 2013; 168: 1186-1194.
    CrossrefPubMedGoogle Scholar
  • 11 Young J. The global epidemiology of heart failure. Med Clin N Am 2004; 88: 1135-1143.
    CrossrefPubMedGoogle Scholar
  • 12 Cleland JGF. et al. for the IMPROVEMENT of Heart Failure Programme Committees and Investigators and the Study Group on Diagnosis of the Working Group on Heart Failure of The European Society of Cardiology. Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey. Lancet 2002; 360: 1631-1639.
    CrossrefPubMedGoogle Scholar
  • 13 Wang TJ. et al. Temporal Relations of Atrial Fibrillation and Congestive Heart Failure and Their Joint Influence on Mortality The Framingham Heart Study. Circulation 2003; 107: 2920-2925.
    CrossrefPubMedGoogle Scholar
  • 14 Olsson LG. et al. Atrial Fibrillation and Risk of Clinical Events in Chronic Heart Failure With and Without Left Ventricular Systolic Dysfunction: Results From the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) Program. J Am Coll Cardiol 2006; 47: 1997-2004.
    CrossrefPubMedGoogle Scholar
  • 15 Krum H. et al. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand.. Guidelines for the prevention, detection and management of chronic heart failure in Australia. 2011 Available at: http://www.heartfoundation.org.au Accessed March 22, 2015.
    PubMedGoogle Scholar
  • 16 Hunt SA. et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119: e391-479.
    CrossrefPubMedGoogle Scholar
  • 17 Lip GY. et al. Heart failure in patients with atrial fibrillation in Europe: a report from the EURObservational Research Programme Pilot survey on Atrial Fibrillation. Eur J Heart Fail. 2015 Epub ahead of print.
    PubMedGoogle Scholar
  • 18 Kim EJ. et al. Predicting outcomes among patients with atrial fibrillation and heart failure receiving anticoagulation with warfarin. Thromb Haemost 2015; 114: 70-77.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Homma S. et al. Warfarin and d Aspirin in Patients with Heart Failure and Sinus Rhythm. N Engl J Med 2012; 366: 1859-1869.
    CrossrefPubMedGoogle Scholar
  • 20 Jasuja GK. et al. Identifying Major Hemorrhage with Automated Data: Results of the Veterans Affairs Study to Improve Anticoagulation (VARIA). Thromb Res 2013; 131: 31-36.
    CrossrefPubMedGoogle Scholar
  • 21 Gallego P. et al. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. Thromb Haemost 2013; 110: 1189-1198.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Connolly SJ. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
    CrossrefPubMedGoogle Scholar
  • 23 Patel MR. et al. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N Engl J Med 2011; 365: 883-891.
    CrossrefPubMedGoogle Scholar
  • 24 Granger C, Alexander J. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Eng J Med 2011; 365: 981-992.
    CrossrefPubMedGoogle Scholar
  • 25 Proietti M, Lip G. Simple decision making between a Vitamin K Antagonist and Non-Vitamin K Antagonist Oral Anticoagulant (NOACs): Using the SAMe-TT2R2 Score. Eur Heart J Cardiovasc Pharm. 2015 Epub ahead of print.
    PubMedGoogle Scholar